Skip to main content
Fig. 6 | Molecular Cancer

Fig. 6

From: Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway

Fig. 6

Recurrent gains are involved in miR-210-3p overexpression in PCa. a The percentage of miR-210-3p with gains in the PCa samples from TCGA. b Percentages and number of miR-210-3p samples with gains in PCa patients with different bone metastasis statues in TCGA dataset (n.s. = no significance). c The percentage of miR-210-3p with gains in our PCa samples. d Percentages and number of miR-210-3p samples with gains in PCa patients with different bone metastasis statues in our PCa samples. P < 0.001. e The average expression level of miR-210-3p in PCa tissues with gains was higher than those without gains in our PCa samples. Each bar represents the median values ± quartile values. P < 0.001. f miR-210-3p expression levels was markedly elevated in metastatic bone tissues compared with that in primary PCa tissues with bone metastasis (PCa/BM, n = 68; Bone, n = 9). P < 0.001. g miR-210-3p expression levels was differentially increased in metastatic bone tissues compared with that in corresponding paired priamy PCa tissues (n = 5). *P < 0.05. h The expression levels of miR-210-3p in the PCa cells under treatment of different concentration of COCl2. *P < 0.05, **P < 0.01 and ***P < 0.001

Back to article page